A case for a non‐transgenic animal model of Alzheimer's disease
暂无分享,去创建一个
[1] Michael T. Heneka,et al. Inflammatory processes in Alzheimer's disease , 2007, Journal of Neuroimmunology.
[2] N. Lazareva,et al. Differential effects of tumor necrosis factor-alpha co-administered with amyloid beta-peptide (25–35) on memory function and hippocampal damage in rat , 2006, Behavioural Brain Research.
[3] Patrick L. McGeer,et al. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease , 2004, Experimental Neurology.
[4] R. Reiter,et al. Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-β onto the hippocampus in vivo , 2004, Journal of Neuroimmunology.
[5] D. Teplow,et al. Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer’s disease , 2004, Neurobiology of Aging.
[6] S. Lipton. Turning down, but not off , 2004, Nature.
[7] T. Nabeshima,et al. Enhanced antidepressant efficacy of σ1 receptor agonists in rats after chronic intracerebroventricular infusion of β-amyloid-(1–40) protein , 2004 .
[8] Jun-Sub Jung,et al. Protection against β-amyloid peptide-induced memory impairment with long-term administration of extract of Angelica gigas or decursinol in mice , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[9] B. Penke,et al. Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease. , 2004, Current protein & peptide science.
[10] J. Guzowski,et al. Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice , 2003, Journal of neurochemistry.
[11] D. Selkoe,et al. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. , 2003, Annual review of pharmacology and toxicology.
[12] Valentina Gelfanova,et al. Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß42 by Inhibiting Rho , 2003, Science.
[13] Anthony R. White,et al. Immunotherapy as a therapeutic treatment for neurodegenerative disorders , 2003, Journal of neurochemistry.
[14] M. Sano. Current Concepts in the Prevention of Alzheimer's Disease , 2003, CNS Spectrums.
[15] Thomas Klockgether,et al. Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-γ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase , 2003, The Journal of Neuroscience.
[16] G. Higgins,et al. Transgenic mouse models of Alzheimer's disease: phenotype and application , 2003, Behavioural pharmacology.
[17] M. Citron,et al. Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease , 2003, The Journal of Neuroscience.
[18] C. Finch,et al. Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[19] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.
[20] M. Lynch,et al. Activation of the c-Jun N-terminal Kinase Signaling Cascade Mediates the Effect of Amyloid-β on Long Term Potentiation and Cell Death in Hippocampus , 2003, Journal of Biological Chemistry.
[21] M. Onufriev,et al. Single intracerebroventricular administration of amyloid-beta (25–35) peptide induces impairment in short-term rather than long-term memory in rats , 2003, Brain Research Bulletin.
[22] S. Davis,et al. Learning deficits and dysfunctional synaptic plasticity induced by aggregated amyloid deposits in the dentate gyrus are rescued by chronic treatment with indomethacin , 2003, The European journal of neuroscience.
[23] G. Krafft,et al. In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.
[24] R. Malinow,et al. APP Processing and Synaptic Function , 2003, Neuron.
[25] M. Onufriev,et al. Administration of Aggregated Beta-Amyloid Peptide (25–35) Induces Changes in Long-Term Potentiation in the Hippocampus in Vivo , 2003, Neuroscience and Behavioral Physiology.
[26] R. L. Richardson,et al. Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Aβ(1–42) injections in the rat , 2002, Brain Research.
[27] D. Selkoe. Alzheimer's Disease Is a Synaptic Failure , 2002, Science.
[28] C. Alberini,et al. Temporally Graded Requirement for Protein Synthesis following Memory Reactivation , 2002, Neuron.
[29] Joseph E LeDoux,et al. Cellular and Systems Reconsolidation in the Hippocampus , 2002, Neuron.
[30] T. Harkany,et al. Pathological peptide folding in Alzheimer's disease and other conformational disorders. , 2002, Current Medicinal Chemistry.
[31] A. Urani,et al. Enhanced antidepressant effect of sigma1 (σ1) receptor agonists in β25–35-amyloid peptide-treated mice , 2002, Behavioural Brain Research.
[32] J. Dodart,et al. Does my mouse have Alzheimer's disease? , 2002, Genes, brain, and behavior.
[33] B. Hyman,et al. Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.
[34] B. Hauss-Wegrzyniak,et al. Chronic Brain Inflammation Results in Cell Loss in the Entorhinal Cortex and Impaired LTP in Perforant Path-Granule Cell Synapses , 2002, Experimental Neurology.
[35] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[36] Y. Ishibashi,et al. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats , 2002, Journal of neurochemistry.
[37] Xin Wu,et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.
[38] D. Alkon,et al. Impairment of Hippocampal CA1 Heterosynaptic Transformation and Spatial Memory by β-Amyloid25–35 , 2002 .
[39] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[40] P. Gebicke-haerter,et al. Microglial activation and amyloid‐β clearance induced by exogenous heat‐shock proteins , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[41] James P. O'Callaghan,et al. Time Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP Mouse , 2002, Experimental Neurology.
[42] Brett Chromy,et al. Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus , 2002, Brain Research.
[43] D. Diamond,et al. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. , 2001, DNA and cell biology.
[44] G. M. Cole,et al. Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology , 2001, Neurobiology of Aging.
[45] H. Annoura,et al. Progressive brain dysfunction following intracerebroventricular infusion of beta1–42-amyloid peptide , 2001, Brain Research.
[46] J. Hardy,et al. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.
[47] S. Davis,et al. Generation of Aggregated β-Amyloid in the Rat Hippocampus Impairs Synaptic Transmission and Plasticity and Causes Memory Deficits , 2001, The Journal of Neuroscience.
[48] D. Small,et al. Alzheimer's disease and Aβ toxicity: from top to bottom , 2001, Nature Reviews Neuroscience.
[49] T. Arendt. Disturbance of neuronal plasticity is a critical pathogenetic event in Alzheimer's disease , 2001, International Journal of Developmental Neuroscience.
[50] R. Terry. An honorable compromise regarding amyloid in Alzheimer disease , 2001, Annals of neurology.
[51] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[52] Brian J. Bacskai,et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy , 2001, Nature Medicine.
[53] R. Anwyl,et al. Use-Dependent Effects of Amyloidogenic Fragments of β-Amyloid Precursor Protein on Synaptic Plasticity in Rat Hippocampus In Vivo , 2001, The Journal of Neuroscience.
[54] C. Herron,et al. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. , 2001, Journal of neurophysiology.
[55] J. Wegiel,et al. The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APPSW mice , 2001, Neurobiology of Aging.
[56] K. Fassbender,et al. Aggregation-Dependent Interaction of the Alzheimers β-Amyloid and Microglia , 2001, Clinical chemistry and laboratory medicine.
[57] J. Blangero,et al. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. , 2000, Science.
[58] M. Owen,et al. Susceptibility locus for Alzheimer's disease on chromosome 10. , 2000, Science.
[59] J. Hardy,et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.
[60] S. Henriksen,et al. In vivo synaptic transmission in young and aged amyloid precursor protein transgenic mice , 2000, Brain Research.
[61] R. Motter,et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.
[62] L. Hertz,et al. Vasopressin increases [Ca2+]i in differentiated astrocytes by activation of V1b/V3 receptors but has no effect in mature cortical neurons , 2000, Journal of neuroscience research.
[63] Kang Hu,et al. High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.
[64] K. Davis,et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.
[65] B. Permanne,et al. In Vivo Reversal of Amyloid‐β Lesions in Rat Brain , 2000 .
[66] B. Sommer,et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[67] M. Mesulam. Neuroplasticity Failure in Alzheimer's Disease Bridging the Gap between Plaques and Tangles , 1999, Neuron.
[68] R. Ferrante,et al. Neurotoxicity and Oxidative Damage of Beta Amyloid 1–42 versus Beta Amyloid 1–40 in the Mouse Cerebral Cortex , 1999, Annals of the New York Academy of Sciences.
[69] Dominic M. Walsh,et al. Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.
[70] T. Nabeshima,et al. Impairments of long-term potentiation in hippocampal slices of beta-amyloid-infused rats. , 1999, European journal of pharmacology.
[71] Gary Lynch,et al. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice , 1999, Brain Research.
[72] L. Lue,et al. Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .
[73] T. Hortobágyi,et al. Neuroprotective approaches in experimental models of β-Amyloid neurotoxicity: Relevance to Alzheimer's disease , 1999, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[74] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[75] L. Bianchi,et al. β(1–40) Amyloid peptide injection into the nucleus basalis of rats induces microglia reaction and enhances cortical γ-aminobutyric acid release in vivo , 1999, Brain Research.
[76] R. Nicoll,et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[77] Veerle Baekelandt,et al. Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain* , 1999, The Journal of Biological Chemistry.
[78] P. Mantyh,et al. Delayed behavioral effects following intrahippocampal injection of aggregated Aβ(1–42) , 1999, Brain Research.
[79] T. Kameyama,et al. Improvement by nefiracetam of β‐amyloid‐(1‐42)‐induced learning and memory impairments in rats , 1999, British journal of pharmacology.
[80] A. Privat,et al. Sigma1 (σ 1) receptor agonists and neurosteroids attenuate β 25–35-amyloid peptide-induced amnesia in mice through a common mechanism , 1998, Neuroscience.
[81] M. Mattson,et al. Effects of amyloid precursor protein derivatives andoxidative stress on basal forebrain cholinergic systems inALZHEIMERS disease , 1998, International Journal of Developmental Neuroscience.
[82] L. Giovannelli,et al. Long-term changes in the aggregation state and toxic effects of β-amyloid injected into the rat brain , 1998, Neuroscience.
[83] T. Hasegawa,et al. Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. , 1998, Japanese journal of pharmacology.
[84] Ronald C. Petersen,et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.
[85] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[86] S D Rogers,et al. Fibrillar -amyloid Induces Microglial Phagocytosis, Expression of Inducible Nitric Oxide Synthase, and Loss of a Select Population of Neurons in the Rat Cns in Vivo , 2022 .
[87] T. Harkany,et al. induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation , 1998 .
[88] E. Sigurdsson,et al. Bilateral Injections of Amyloid-β 25-35 into the Amygdala of Young Fischer Rats: Behavioral, Neurochemical, and Time Dependent Histopathological Effects , 1997, Neurobiology of Aging.
[89] W. K. Cullen,et al. Block of LTP in rat hippocampus in vivo by β‐amyloid precursor protein fragments , 1997 .
[90] J. Overmier,et al. Intrahippocampal Injections of Exogenous β-Amyloid Induce Postdelay Errors in an Eight-Arm Radial Maze , 1997, Neurobiology of Learning and Memory.
[91] A. Privat,et al. In vitro aggregation facilitates β-amyloid peptide-(25–35)-induced amnesia in the rat , 1997 .
[92] W. K. Cullen,et al. β‐Amyloid produces a delayed NMDA receptor‐ dependent reduction in synaptic transmission in rat hippocampus , 1996, Neuroreport.
[93] P. Soubrié,et al. Administration of amyloid β-peptides in the rat medial septum causes memory deficits: reversal by SR 57746A, a non-peptide neurotrophic compound , 1996, Neuroscience Letters.
[94] W. Yang,et al. Novel purification and detailed characterization of perlecan isolated from the Engelbreth-Holm-Swarm tumor for use in an animal model of fibrillar A beta amyloid persistence in brain. , 1996, Journal of biochemistry.
[95] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[96] Christopher A. Shaw,et al. An alternative to the LTP orthodoxy: a plasticity-pathology continuum model , 1996, Brain Research Reviews.
[97] C. Barnes,et al. The neurochemical and behavioral effects of β-amyloid peptide(25–35) , 1996, Brain Research.
[98] G. Cole,et al. Rodent models of Alzheimer's disease: Rat aβ infusion approaches to amyloid deposits , 1996, Neurobiology of Aging.
[99] M. Ball,et al. Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*) , 1996, The Journal of Biological Chemistry.
[100] A. Privat,et al. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction , 1996, Brain Research.
[101] D. Pollen,et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.
[102] P. Mantyh,et al. Beta-amyloid(1–40) effects on behavior and memory , 1995, Brain Research.
[103] D. Neill. Alzheimer's disease: maladaptive synaptoplasticity hypothesis. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[104] L. Giovannelli,et al. Differential effects of amyloid peptides β-(1–40) and β-(25–35) injections into the rat nucleus basalis , 1995, Neuroscience.
[105] L. Thal,et al. Lack of long-term effects after β-amyloid protein injections in rat brain , 1994, Neurobiology of Aging.
[106] J. Overmier,et al. Effects of an exogenous β-amyloid peptide on retention for spatial learning , 1994 .
[107] S. Younkin,et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.
[108] T. Hasegawa,et al. β-Amyloid protein-induced Alzheimer's disease animal model , 1994, Neuroscience Letters.
[109] R. Kalaria,et al. Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. , 1994, American Journal of Pathology.
[110] S. Younkin,et al. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. , 1993, Science.
[111] D. Selkoe,et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.
[112] M. Rossor,et al. Familial Alzheimer's disease. , 1992, Bailliere's clinical neurology.
[113] D. K. Rush,et al. Intracerebral /sB-amyloid(25–35) produces tissue damage: Is it neurotoxic? , 1992, Neurobiology of Aging.
[114] C. Geula,et al. The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected β-amyloid in the rat brain , 1992, Neurobiology of Aging.
[115] L. Thal,et al. Solvent effects on beta protein toxicity in vivo , 1992, Neurobiology of Aging.
[116] D. Stephenson,et al. Implants containing β-amyloid protein are not neurotoxic to young and old rat brain , 1992, Neurobiology of Aging.
[117] G. Cole,et al. Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. , 1992, The American journal of pathology.
[118] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[119] D. Salmon,et al. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.
[120] T. Wisniewski,et al. Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. , 1991, Biochemical and biophysical research communications.
[121] M. Beal,et al. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[122] K. Kristensson,et al. Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease , 1991, Lipids.
[123] J. Morley,et al. Amnestic effects in mice of four synthetic peptides homologous to amyloid beta protein from patients with Alzheimer disease. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[124] M. Sporn,et al. Deactivation of macrophages by transforming growth factor-β , 1988, Nature.
[125] D. Mann,et al. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease , 1987, Journal of the Neurological Sciences.
[126] S. Guénette. Mechanisms of Aβ clearance and catabolism , 2007, NeuroMolecular Medicine.
[127] T. Nabeshima,et al. Enhanced antidepressant efficacy of sigma1 receptor agonists in rats after chronic intracerebroventricular infusion of beta-amyloid-(1-40) protein. , 2004, European Journal of Pharmacology.
[128] A. A. Yakovlev,et al. Effects of tumor necrosis factor‐alpha central administration on hippocampal damage in rat induced by amyloid beta‐peptide (25–35) , 2003, Journal of neuroscience research.
[129] I. Goshen,et al. Impaired interleukin‐1 signaling is associated with deficits in hippocampal memory processes and neural plasticity , 2003, Hippocampus.
[130] L. Launer. Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. , 2003, Drugs.
[131] Michael T Heneka,et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[132] S. Guénette. Mechanisms of Abeta clearance and catabolism. , 2003, Neuromolecular medicine.
[133] W Blaine Stine,et al. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. , 2002, Brain research.
[134] P. Gebicke-haerter,et al. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[135] A. Urani,et al. Enhanced antidepressant effect of sigma(1) (sigma(1)) receptor agonists in beta(25-35)-amyloid peptide-treated mice. , 2002, Behavioural Brain Research.
[136] D. Alkon,et al. Impairment of hippocampal CA1 heterosynaptic transformation and spatial memory by beta-amyloid(25-35). , 2002, Journal of neurophysiology.
[137] D. Small,et al. Alzheimer's disease and Abeta toxicity: from top to bottom. , 2001, Nature reviews. Neuroscience.
[138] L. Mucke,et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. , 2001, Nature medicine.
[139] J. Hardy,et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. , 2000, Nature.
[140] B. Permanne,et al. In vivo reversal of amyloid-beta lesions in rat brain. , 2000, Journal of neuropathology and experimental neurology.
[141] Q S Chen,et al. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. , 2000, Journal of neuroscience research.
[142] L. Lue,et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. , 1999, The American journal of pathology.
[143] L. Bianchi,et al. Beta(1-40) amyloid peptide injection into the nucleus basalis of rats induces microglia reaction and enhances cortical gamma-aminobutyric acid release in vivo. , 1999, Brain research.
[144] W. K. Cullen,et al. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. , 1997, Neuroreport.
[145] A. Privat,et al. In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat. , 1997, European journal of pharmacology.
[146] C. Barnes,et al. The neurochemical and behavioral effects of beta-amyloid peptide(25-35). , 1996, Brain research.
[147] L. Giovannelli,et al. Differential effects of amyloid peptides beta-(1-40) and beta-(25-35) injections into the rat nucleus basalis. , 1995, Neuroscience.
[148] J. Overmier,et al. Effects of an exogenous beta-amyloid peptide on retention for spatial learning. , 1994, Behavioral and neural biology.
[149] L. Thal,et al. Lack of long-term effects after beta-amyloid protein injections in rat brain. , 1994, Neurobiology of aging.
[150] D. Selkoe,et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. , 1992, Nature.
[151] M. Sporn,et al. Deactivation of macrophages by transforming growth factor-beta. , 1988, Nature.